XML 42 R35.htm IDEA: XBRL DOCUMENT
v3.25.1

Net Loss Per Share Attributable to Common Stockholders (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Earnings Per Share [Abstract] |
Schedule of Calculation for Basic and Diluted Net Loss Per Share | The following table presents the calculation for basic and diluted net loss per share (in thousands, except share and per share data):
|  | Three Months Ended March 31, |
|  | 2025 | 2024 |
Numerator: |  |  |  |  |  |
Net loss |  | $ | (68,037 | ) |  | $ | (64,743 | )
Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares |  |  | — |  |  |  | (27,807 | )
Cumulative undeclared dividends on Series C preferred shares |  |  | — |  |  |  | (506 | )
Net loss attributable to common stockholders |  | $ | (68,037 | ) |  | $ | (93,056 | )
Denominator: |  |  |  |  |  |
Weighted-average common shares outstanding, basic and diluted |  |  | 170,506 |  |  |  | 63,430 |
Net loss per share attributable to common stockholders, basic and diluted |  | $ | (0.40 | ) |  | $ | (1.47 | )
Schedule of Antidilutive Securities Excluded From the Computation of Earnings Per Share | The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share for each period, as the impact of including them would have been anti-dilutive. As disclosed in Note 10, the Company issued a warrant for $100 million in shares of the Company’s Class A common stock. As per the terms of the warrant, potentially dilutive shares are based on the latest equity financing price. The warrant was terminated for no consideration on December 31, 2024.
|  | As of March 31, |
|  | 2025 |  |  | 2024 |
Stock options outstanding |  |  | — |  |  |  | 210,000 |
Convertible preferred stock |  |  | — |  |  |  | 63,603,084 |
Astrazeneca warrant |  |  | — |  |  |  | 1,744,991 |
Deep 6 holdback liability |  |  | 17,372 |  |  |  | — |
SEngine holdback liability |  |  | — |  |  |  | 41,007 |
Unvested RSUs |  |  | 5,761,861 |  |  |  | — |
Unvested RSAs |  |  | 26,059 |  |  |  | — |
Allen & Company warrant |  |  | — |  |  |  | 150,000 |
Total potentially dilutive shares |  |  | 5,805,292 |  |  |  | 65,749,082 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration